Insiders are also snapping up a large amount of stock in Alnylam Pharmaceuticals ( ALNY), a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Insiders are buying into big time strength here since shares of Alnylam Pharmaceuticals are up over 58% so far in 2012. Alnylam Pharmaceuticals market cap of $557 million and an enterprise value of $404 million. This stock trades at a reasonable valuation, with a price-to-sales of 6.66 and a price-to-book of 4.62. Its estimated growth rate for this year is 3.7%, and for next year it's pegged at -73.3%. This is a cash-rich company, since the total cash position on its balance sheet is $146.40 million and its total debt is zero. A director just bought 93,000 shares, or about $1 million worth of stock, at $10.75 per share. From a technical perspective, ALNY is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been in a monster uptrend for the past two months and change, with the stock rising from its November low of $6.50 to its current price of just above $13 a share. During that huge uptrend, this stock has been consistently making higher lows and higher highs, which is bullish price action. Now the stock is within range of triggering a near-term breakout trade. If you're bullish ALNY, I would look for long-biased trades once this stock breaks out above some near-term overhead resistance at $12.99 to $13.25 a share with big volume. Look for volume on that move that registers near or well above its three-month average volume of 433,223 shares. At last check, ALNY has hit a high today of $13.19 and volume is just over 200,000 shares. I also featured ALNY recently in " 8 Stocks Rising on Huge Volume." To see more stocks with notable insider buying like AutoNation ( AN), Genomic Health ( GHDX) and Geoeye ( GEOY), check out the Stocks With Big Insider Buying portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.